Abrezekimab

Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma[1].

Product Specifications

CAS Number

[2043952-59-4]

Product Name Alternative

UCB4144; VR 942

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/abrezekimab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Abrezekimab]

Molecular Weight

(48.1 kDa)

References & Citations

[1]Burgess G, et, al. Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942. EBioMedicine. 2018 Sep;35:67-75.